Lost In The Middle: Why Value Added Products Need Better Pricing Mechanisms
This article was originally published in Scrip
Europe needs better pricing systems for so-called value added medicines if the market for such products is to be sustainable or attractive, Warrick Smith, director general of the British Generic Manufacturers Association, the BGMA, told Scrip.
You may also be interested in...
WTO member states including the EU, the US and the UK argue that waiving certain IP rights is unnecessary for enhancing responses to the Covid-19 pandemic.
Insurers argue that better use of real world data and multiple pricing assessments could help lower drug prices in Germany.
To keep investors happy, companies will have to start showing that their high-priced advanced therapies offset costs elsewhere in the health care system.